A Phase 1/2 interventional study of AL001 and Placebo in Alzheimer's Disease and Healthy Non-elderly and Elderly Adults, sponsored by Alzamend Neuro, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Alzamend Neuro, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 837th largest by enrollment of the 1,609 interventional ones that give a count, is one of 131 that started in 2022, is one of 67 in phase 1/2, and was the 1,448th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 131 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
Alzamend Neuro, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Alzamend Neuro, Inc. has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.
This is a Phase 1/2a, multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose (MTD) of AL001, a crystal engineered lithium-salicylate-proline lithium delivery product that in nonclinical studies was shown to enhance and prolong the pharmacokinetic (PK) profile of lithium in the brain with enhanced efficacy potential in Alzheimer's models compared to lithium carbonate.
A maximum of approximately 72 participants will be enrolled. Participants will be randomly assigned to receive study drug (active AL001) or placebo in a ratio of 6:2, respectively, with 8 patients in each dosing cohort. Placebos will be pooled and regarded as a comparative cohort for safety.
Cohorts 2a, 3a, 4a and 5a will involve 1:1 healthy non-elderly and elderly subjects; cohorts 1, 2b, 3b, 4b and 5b will involve Alzheimer's subjects. The study will consist of a screening period (Days -28 to -2), a 14-day treatment period, and a 42-day follow-up period.
Inclusion Criteria (Alzheimer's Patients):
Exclusion Criteria (Alzheimer's Patients):
Central nervous system-related exclusions:
Systemic related exclusions:
Inclusion criteria (Healthy Subjects):
Exclusion criteria (Healthy Subjects)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive AL001. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort. A total of 9 cohorts will receive 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits. Cohort 1 will include 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) will receive the following treatment or placebo: • Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily ×14 days, given as 3 × 210 mg AL001 capsules TID)
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID).
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 3 will be sub-divided into 2 cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 3a and 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID)
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID)
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID)
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 2b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID).
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID)
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 4b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID)
Drug: AL001 · Other: Placebo
The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 5b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 5b: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID).
Drug: AL001 · Other: Placebo
a crystal engineered lithium-salicylate-proline lithium delivery product
Also known as: Alzamend AL001
matching placebo formulation
Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.
To evaluate the safety and tolerability of AL001 in healthy subjects and patients with adverse event(s), AD, descriptive statistics will be presented by treatment group for each cohort and overall, for the following: Proportion of participants with treatment-emergent adverse events (TEAEs) * Proportion of participants with serious AEs * Proportion of participants with TEAEs that lead to premature discontinuation * Proportion of participants with abnormal values for each safety laboratory test (change from baseline) * Proportion of participants with abnormal values for each Electrocardiogram (ECG) parameter (change from baseline in standard 12-lead ECG parameters) For all analyses, placebo-treated subjects from each Cohort were combined (pooled) to provide a composite placebo group for all comparisons. Adverse event profiles for all treated subjects were benign as were placebo-treated subjects. No further statistical analyses were therefore appropriate.
Time frame: 42 days with a 14-day treatment period
Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001
To characterize the MTD of AL001 in all subjects treated with AL001: • Proportion of subjects in each Cohort with plasma trough measurements of lithium \> 1.0 mEq/L. Subjects above these values invoke stopping rules for subsequent cohort enrollment.
Time frame: 42 days with a 14-day treatment period
Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects
To characterize the MTD of AL001 in all subjects: • Proportion of all subjects with plasma maximum concentration (Cmax) measurements for salicylate \> 30 mg/dL
Time frame: 42 days with a 14-day treatment period
| Milestone | Multiple Ascending Doses of AL001 - Cohort 1 | Multiple Ascending Doses of AL001 - Cohort 2a | Multiple Ascending Doses of AL001 - Cohort 2b | Multiple Ascending Doses of AL001 - Cohort 3a | Multiple Ascending Doses of AL001 - Cohort 3b | Multiple Ascending Doses of AL001 - Cohort 4a | Multiple Ascending Doses of AL001 - Cohort 4b | Multiple Ascending Doses of AL001 - Cohort 5a | Multiple Ascending Doses of AL001 - Cohort 5b | Combined Placebo Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 16 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 16 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To evaluate the safety and tolerability of AL001 in healthy subjects and patients with adverse event(s), AD, descriptive statistics will be presented by treatment group for each cohort and overall, for the following: Proportion of participants with treatment-emergent adverse events (TEAEs) * Proportion of participants with serious AEs * Proportion of participants with TEAEs that lead to premature discontinuation * Proportion of participants with abnormal values for each safety laboratory test (change from baseline) * Proportion of participants with abnormal values for each Electrocardiogram (ECG) parameter (change from baseline in standard 12-lead ECG parameters) For all analyses, placebo-treated subjects from each Cohort were combined (pooled) to provide a composite placebo group for all comparisons. Adverse event profiles for all treated subjects were benign as were placebo-treated subjects. No further statistical analyses were therefore appropriate.
| Participants | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1 | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2a | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2b | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3a | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3b | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4a | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4b | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5a | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5b | Multiple Ascending Doses of AL001 - Pooled Placebo Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Serious AEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TEAEs that lead to premature discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 |
| Abnormal values for safety laboratory tests (change from baseline) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | — | 0 |
| abnormal ECG parameters (change from baseline) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 |
| No Adverse Events observed | 6 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | — | 16 |
To characterize the MTD of AL001 in all subjects treated with AL001: • Proportion of subjects in each Cohort with plasma trough measurements of lithium \> 1.0 mEq/L. Subjects above these values invoke stopping rules for subsequent cohort enrollment.
| Proportion of Subjects | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 1 | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 2a | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 2b | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 3a | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 3b | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 4a | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 4b | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 5a | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 5b | Multiple Ascending Doses of AL001 - Pooled Placebo Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.167 | — | 0 |
To characterize the MTD of AL001 in all subjects: • Proportion of all subjects with plasma maximum concentration (Cmax) measurements for salicylate \> 30 mg/dL
| Proportion of Subjects | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 1 | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 2a | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 2b | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 3a | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 3b | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 4a | Multiple Ascending Doses of AL001 in AD Subjects - Cohort 4b | Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 5a | Multiple Ascending Doses of AL001 - Pooled Placebo Group |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.167 | 0 |
Collected over 42 days with a 14 day treatment period per cohort (phone call follow-up on day 42 to confirm safety). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AD in Cohort 1 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| AD on Cohort 2 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| AD in Cohort 3 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| AD in Cohort 4 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Healthy Subjects in Cohort 2 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Healthy Subjects in Cohort 3 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Healthy Subjects in Cohort 4 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Healthy Subjects in Cohort 5 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| AD Subjects on Placebo | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Healthy Subjects on Placebo | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Event | AD in Cohort 1 | AD on Cohort 2 | AD in Cohort 3 | AD in Cohort 4 | Healthy Subjects in Cohort 2 | Healthy Subjects in Cohort 3 | Healthy Subjects in Cohort 4 | Healthy Subjects in Cohort 5 | AD Subjects on Placebo | Healthy Subjects on Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| GastrointestinalGastrointestinal disorders | 0/6 | 0/6 | 2/6 | 2/6 | 2/6 | 4/6 | 2/6 | 4/6 | 0/8 | 3/8 |
| InvestigationsInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 3/6 | 3/6 | 1/8 | 0/8 |
| Nervous SystemNervous system disorders | 0/6 | 0/6 | 2/6 | 1/6 | 1/6 | 2/6 | 1/6 | 2/6 | 1/8 | 1/8 |
| RespiratoryRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 2/6 | 0/8 | 0/8 |
| PsychiatricPsychiatric disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 2/6 | 0/8 | 1/8 |
| SkinSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 1/6 | 1/6 | 1/8 | 2/8 |
| Renal and UrinaryRenal and urinary disorders | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/8 | 0/8 |
| Procedural complicationsInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/8 | 1/8 |
| MusculoskeletalMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 | 1/8 |
| Ear LabyrinthEar and labyrinth disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 | 0/8 |
Cohort 1 (AD subject), n=6 randomized to AL001(1 withdrawal before dosing). Cohort 2a (healthy volunteers \[HV\]): n=6 rand. to AL001. Cohort 2b (AD): n=6 rand. to AL001. Cohort 3a (HV): n=6 rand. to AL001. Cohort 3b (AD): n=6 rand. to AL001. Cohort 4a (HV): n=6 rand. to AL001. Cohort 4b (AD): n=6 rand. to AL001. Cohort 5 (HV), n=6 rand. to AL001. Combined Placebo Group, n=16.
| Age, Customized(years) | Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days) | Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days) | Combined Placebo Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.1 (56 to 71) | 65.4 (52 to 77) | 65.4 (52 to 77) | 57.5 (24 to 72) | 57.5 (24 to 72) | 58.8 (32 to 74) | 58.8 (32 to 74) | 57.3 (33 to 70) | — | 59.4 (24 to 75) | 60.2 (24 to 77) |
| Sex: Female, Male(Participants) | Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days) | Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days) | Combined Placebo Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 4 | 5 | 1 | 4 | 2 | 4 | 2 | — | 12 | 34 |
| Male | 7 | 2 | 1 | 5 | 2 | 4 | 2 | 4 | — | 4 | 31 |
| Race (NIH/OMB)(Participants) | Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days) | Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days) | Combined Placebo Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Black or African American | 6 | 0 | 4 | 2 | 4 | 0 | 5 | 0 | — | 7 | 28 |
| White | 1 | 6 | 2 | 4 | 2 | 6 | 1 | 6 | — | 9 | 37 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Ratio of Plasma Lithium trough >1.0mEq/L or plasma salicylate peak concentrations >30mg/dL(ratio) | Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days) | Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days) | Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days) | Combined Placebo Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Apr 2023, 11 months.
Results were first posted in May 2025, 2 years 1 month after primary completion.
Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Latozinemab
Alzamend Neuro, Inc.